Fulhold Pharma

Fulhold Pharma is a clinical-stage biotechnology company specializing in the development of Carbohydrate Derived Fulvic Acid (CHD-FA), a patented, high-purity pharmaceutical-grade organic acid. The company's proprietary platform produces CHD-FA with potent antimicrobial, anti-inflammatory, and antioxidant properties, positioning it as a novel treatment for drug-resistant infections and chronic inflammatory conditions. Fulhold is currently advancing its lead candidate through Phase 2 clinical trials for indications such as eczema and various bacterial and fungal infections. By leveraging the unique multi-target mechanism of CHD-FA, the company aims to address the global challenge of antimicrobial resistance (AMR). Fulhold operates with a corporate presence in the United Kingdom and significant research and manufacturing facilities in South Africa.